Special Investigation (Long-term Investigation) in Patients With Crohn's Disease

Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)

NCT01960790 ·Status: COMPLETED

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

NCT02185014 ·Status: COMPLETED ·Phase: PHASE3

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00105300 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

NCT01235689 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

NCT00686374 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00055523 ·Status: COMPLETED ·Phase: PHASE2

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362 ·Status: ACTIVE_NOT_RECRUITING

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

NCT02499783 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353 ·Status: RECRUITING ·Phase: PHASE3

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

NCT03884439 ·Status: COMPLETED

Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00409617 ·Status: COMPLETED ·Phase: PHASE3

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

NCT01674413 ·Status: WITHDRAWN ·Phase: PHASE3

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

NCT05068284 ·Status: TERMINATED ·Phase: PHASE2

Study Evaluating rhIL-11 in Active Crohn's Disease

NCT00040521 ·Status: COMPLETED ·Phase: PHASE2

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

NCT02015793 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Immune Ablation and Stem Cell Support for Crohn's Disease

NCT00179842 ·Status: WITHDRAWN ·Phase: PHASE2

HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease

NCT05813860 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients

NCT00676988 ·Status: COMPLETED

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

NCT00427921 ·Status: COMPLETED ·Phase: PHASE3

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00077779 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

NCT02403323 ·Status: TERMINATED ·Phase: PHASE3